Viking Therapeutics, Inc.

Quick facts

Phase 3 pipeline

• VK2735 · Endocrinology, Obesity, Diabetes
  VK2735 is a dual GLP-1/GCG receptor agonist that activates both glucagon-like peptide-1 and glucagon signaling pathways to promote weight loss and improve metabolic parameters.

Phase 2 pipeline

• VK2809

Phase 1 pipeline

• VK0214
• VK2735 Drug

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Viking Therapeutics, Inc. portfolio CI brief
• Viking Therapeutics, Inc. pipeline updates RSS